STOCK MARKET Glenmark shares surge 4% following positive Phase 1 trial results for ISB 2001 Dec 10, 2024
CORPORATES Ichnos Glenmark Innovation announces promising Phase 1 results for trispecific antibody ISB 2001 in relapsed multiple myeloma, showing 75% response rate Nov 6, 2024